Current drug-eluting stents in complex patients and lesions

Minerva Cardioangiologica

Volumn 54, Issue 1, 2006, Pages 5-22

  Elezi, S ^a   Dibra, A ^a   Schomig A ^a   Kastrati, A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Angioplasty, transluminal, percutaneous coronary; Complex lesions; Coronary restenosis; Diabetes mellitus; Drug eluting stents

Indexed keywords

7 HEXANOYLTAXOL; ABCIXIMAB; ANTITHROMBOCYTIC AGENT; BATIMASTAT; BIOLIMUS; DACTINOMYCIN; ESTRADIOL; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; METAL; MYCOPHENOLIC ACID; PACLITAXEL; PACLITAXEL DERIVATIVE; POLYMER; RAPAMYCIN; TIROFIBAN; TSUKUBAENOLIDE; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ACUTE HEART INFARCTION; ARTICLE; BIODEGRADABLE IMPLANT; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; HIGH RISK PATIENT; HUMAN; IN-STENT RESTENOSIS; LEFT CORONARY ARTERY; LONG TERM CARE; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PERFORMANCE; SAPHENOUS VEIN GRAFT;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; DIABETIC ANGIOPATHIES; DRUG ADMINISTRATION ROUTES; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; STENTS;

EID: 33644756906     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (122)

1. Petersen S, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A. European cardiovascular disease statistics 2005. BHF: London; 2005. http://www.heartstats.org/uploads/documents%5CPDF.pdf.
2. Reddy KS. Cardiovascular disease in non-Western countries. N Engl J Med 2004;350:2438-40.
3. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978;1:263.
4. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61-8.
5. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701-6.
6. Al Suwaidi J, Berger PB, Holmes DR Jr. Coronary artery stents. JAMA 2000;284:1828-36.
7. Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997;30:1428-36.
8. Bauters C, Hubert E, Prat A, Bougrimi K, Van Belle E, McFadden EP et al. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol 1998;31:1291-8.
9. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part I. Circulation 2003;107:2274-9.
10. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part II. Circulation 2003;107:2383-9.
11. Rogers CD. Drug-eluting stents: clinical perspectives on drug and design differences. Rev Cardiovasc Med 2005;6 Suppl 1:S3-12.
12. Wessely R, Hausleiter J, Michaelis C, Jaschke B, Vogeser M, Milz S et al. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol 2005;25:748-53.
13. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
14. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
15. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94.
16. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
17. Gershlick AH. Drug eluting stents in 2005. Heart 2005;91 Suppl 3:24-31.
18. Hausleiter J, Kastrati A, Wessely R, Dibra A, Mehilli J, Schratzenstaller T et al. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J 2005;26:1475-81.
19. Serruys PW, Ormiston JA, Sianos G, Sousa JE, Grube E, den Heijer P et al. Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. J Am Coll Cardiol 2004;44:1363-7.
20. Grube E, Lansky A, Hauptmann KE, Di Mario C, Di Sciascio G, Colombo A et al. High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. J Am Coll Cardiol 2004;44:1368-72.
21. Morice MC. JUPITER-II: A prospective randomized trial of a tacrolimus-eluting stent compared to a carbon-coated stent in patients with coronary artery disease. Transcatheter Cardiovascular Therapeutics Conference; 2005, October 16-21, Washington, DC.
22. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-21.
23. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
24. Wessely R, Kastrati A, Schomig A. Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent. Ann Intern Med 2005;143:392-4.
25. Fears of catch-up phenomenon mar otherwise positive 12-month results for ENDEAVOR I. http://theheart.org/viewArticle.do?simpleName=568842).
26. Virmani R. Complications of percutaneous coronary intervention - pathology. ESC Congress 2004 - Munich. http://www.escardio.org/knowledge/ OnlineLearning/sl ides/ESC_Congress_2004_Munich/RVirmaniFP239/.
27. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-5.
28. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C et al. Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European society of cardiology. Eur Heart J 2005;26:804-47.
29. Percutaneous Coronary Intervention: ACC/AHA/SCAI 2005 Guideline Update for (Update of the 2001 PCI Guidelines). http://www.acc.org/clinical/guidelines/ percutaneous/update/index.pdf).
30. Virmani R, Kolodgie FD, Farb A, Lafont A. Drug eluting stents: are human and animal studies comparable? Heart 2003;89:133-8.
31. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol 2004;44:1373-85.
32. Kastrati A, Dibra A, Eberle S, Mehilli J, Suarez de Lezo J, Goy JJ et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 2005;294:819-25.
33. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005;293:165-71.
34. Dibra A, Kastrati A, Mehilli J, Pache J, Schühlen H, von Beckerath N et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-70.
35. Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005;353:653-62.
36. Late lumen loss a problem once again for the new Endeavor stent. http://theheart.org/viewArticle.do? primaryKey=578713&from=/searchLayout.do)
37. Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 2006;113:273-9.
38. Mauri L, Orav EJ, Kuntz RE. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 2005;111:3435-42.
39. Mauri L, Orav EJ, Candia SC, Cutlip DE, Kuntz RE. Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation 2005;112:2833-9.
40. Kereiakes DJ, Kuntz RE, Mauri L, Krucoff MW. Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. J Am Coll Cardiol 2005;45:1206-12.
41. Morice MC. Eight-month outcome of the Reality Study: a prospective, randomized, multi-center head-to-head comparison of the sirolimus-eluting stent (Cypher) and the paclitaxel-eluting stent (Taxus). American College of Cardiology Annual Scientific Session, 2005, March 6-9, Orlando, FL.
42. de Lezo J, Medina A, Pan M, Romero M, Delgado A, Segura J et al. Drug-eluting stents for complex lesions: randomized rapamycin versus paclitaxel CORPAL study. J Am Coll Cardiol 2005;45:75A.
43. de Lezo JS, Medina A, Pan M, Romero M, Segura F, Delgado A et al. Drug-eluting stents for the treatment of chronic total occlusion. A randomized comparison of rapamycin versus paclitaxel-eluting stents. American Heart Association Annual Scientific Session; 2005, November 13-16, Dallas, TX.
44. Pan M, de Lezo JS, Medina A, Romero M, Segura J, Ojeda S et al. Drug eluting-stents for the treatment of bifurcation lesions: a randomized comparison between paclitaxel and sirolimus stents. American Heart Association Annual Scientific Session; 2005, November 13-16, Dallas, TX.
45. Segura F, de Lezo JS, Medina A, Pan M, Romero M, Delgado A et al. A randomized comparison: drug-eluting stents for the treatment of small vessel size (<2.5 mm diameter) coronary artery disease. American Heart Association Annual Scientific Session; 2005, November 13-16, Dallas, TX.
46. Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schömig A. Randomised trial of paclitaxel-eluting stents and sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006;27:260-6.
47. Edelman ER, Rogers C. Stent-versus-stent equivalency trials: are some stents more equal than others? Circulation 1999;100:896-8.
48. Hausleiter J, Kastrati A, Mehilli J, Schuhlen H, Pache J, Dotzer F et al. Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: results from the ISAR-STEREO trial. Am Heart J 2003;146:882-6.
49. Goy JJ, Stauffer JC, Siegenthaler M, Benoit A, Seydoux C. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXI trial. J Am Coll Cardiol 2005;45:308-11.
50. Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005;366:921-9.
51. Elezi S, Kastrati A, Hadamitzky M, Dirschinger J, Neumann FJ, Schömig A. Clinical and angiographic follow-up after balloon angioplasty with provisional stenting for coronary in-stent restenosis. Cathet Cardiovasc Intervent 1999;48:151-6.
52. Mehran R, Dangas G, Mintz GS, Waksman R, Abizaid A, Satler LF et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty versus rotational atherectomy: comparative mechanisms and results. Circulation 2000;101:2484-9.
53. Brenner DJ, Miller RC. Long-term efficacy of intracoronary irradiation in inhibiting in-stent restenosis. Circulation 2001;103:1330-2.
54. Saia F, Lemos PA, Arampatzis CA, Hoye A, Degertekin M, Tanabe K et al. Routine sirolimus eluting stent implantation for unselected in-stent restenosis: insights from the rapamycin eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Heart 2004;90:1183-8.
55. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ et al. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003;107:559-64.
56. Iofina E, Radke PW, Skurzewski P, Haager PK, Blindt R, Koch KC et al. Superiority of sirolimus eluting stent compared with intracoronary beta radiation for treatment of in-stent restenosis: a matched comparison. Heart 2005;91:1584-9.
57. Iofina E, Haager PK, Radke PW, Langenberg R, Blindt R, Ortlepp J et al. Sirolimus- and paclitaxel-eluting stents in comparison with balloon angioplasty for treatment of in-stent restenosis. Catheter Cardiovasc Interv 2005;64:28-34.
58. Neumann FJ, Desmet W, Grube E, Brachmann J, Presbitero P, Rubartelli P et al. Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement. Circulation 2005;111:2107-11.
59. Alfonso F, Bethencourt A, Lopez-Minguez JR, Mantilla R, Angel J, Perez-Vizcayno MJ et al. The RIBS II (Restenosis Intra-stent: Balloon angioplasty versus rapamycin-eluting Stenting) randomised study. European Society of Cardiology (ESC) Congress; 2005, September 3-7, Stockholm, Sweden.
60. Holmes DR. SISR: Sirolimus-eluting stent vs brachytherapy in patients with bare metal in-stent. Transcatheter Cardiovascular Therapeutics Conference; 2005. October 16-21, Washington, DC.
61. Seung KB, Kim YH, Park DW, Lee BK, Lee CW, Hong MK et al. Effectiveness of sirolimus-eluting stent implantation for the treatment of ostial left anterior descending artery stenosis with intravascular ultrasound guidance. J Am Coll Cardiol 2005;46:787-92.
62. Iakovou I, Ge L, Michev I, Sangiorgi GM, Montorfano M, Airoldi F et al. Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions. J Am Coll Cardiol 2004;44:967-71.
63. Garot P, Lefevre T, Savage M, Louvard Y, Bamlet WR, Willerson JT et al. Nine-month outcome of patients treated by percutaneous coronary interventions for bifurcation lesions in the recent era: a report from the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. J Am Coll Cardiol 2005;46:606-12.
64. Dzavik P. Progress in percutaneous management of coronary bifurcation lesions. Minerva Cardioangiol 2005;53:379-401.
65. Iakovou I, Ge L, Colombo A. Contemporary stent treatment of coronary bifurcations. J Am Coll Cardiol 2005;46:1446-55.
66. Colombo A. ARTS II Substudy: cypher stents perform well in bifurcation lesions. American Heart Association Annual Scientific Session; 2005, November 13-16, Dallas, TX.
67. Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR Jr, Spanos V et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 2004;109:1244-9.
68. Pan M, de Lezo JS, Medina A, Romero M. Segura J, Pavlovic D et al. Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus complex strategy. Am Heart J 2004;148:857-64.
69. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005;294:1215-23.
70. Ge L, Airoldi F, Iakovou I, Cosgrave J, Michev I, Sangiorgi GM et al. Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation. J Am Coll Cardiol 2005;46:613-20.
71. Ge L, Iakovou I, Cosgrave J, Agostoni P, Airoldi F, Sangiorgi GM et al. Treatment bifurcation lesions with two stents: crush versus T stenting - one year angiographic and clinical follow-up. Heart 2005 Jun 17; [Epub ahead of print]
72. Hoye A, van Mieghem CA, Ong AT, Aoki J, Rodriguez Granillo GA, Valgimigli M et al. Percutaneous therapy of bifurcation lesions with drug-eluting stent implantation: the Culotte technique revisited. Int J Cardiovasc Intervent 2005;7:36-40.
73. Bell MR, Berger PB, Bresnahan JF, Reeder GS, Bailey KR, Holmes DR Jr. Initial and long-term outcome of 354 patients after coronary balloon angioplasty of total coronary artery exclusions. Circulation 1992;85:1003-11.
74. Sirnes PA, Golf S, Myreng Y, Molstad P, Emanuelsson H, Albertsson P et al. Stenting in Chronic Coronary Occlusion (SICCO): a randomized, controlled trial of adding stent implantation after successful angioplasty. J Am Coll Cardiol 1996;28:1444-51.
75. Elezi S, Kastrati A, Wehinger A, Walter H, Schuhlen H, Hadamitzky M et al. Clinical and angiographic outcome after stent placement for chronic coronary occlusion. Am J Cardiol 1998;82:803-6.
76. 7o. Leon M. Cypher update, DES Revolution IV. American College of Cardiology Annual Scientific Session; 2005, March 6-9, Orlando, FL.
77. Werner GS, Krack A, Schwarz G, Prochnau D, Betge S, Figulla HR. Prevention of lesion recurrence in chronic total coronary occlusions by paclitaxel-eluting stents. J Am Coll Cardiol 2004;44:2301-6.
78. Nakamura S, Muthusamy TS, Bae JH, Cahyadi YH, Udayachalerm W, Tresukosol D. Impact of sirolimus-eluting stent on the outcome of patients with chronic total occlusions. Am J Cardiol 2005;95:161-6.
79. Ge L, Iakovou I, Cosgrave J, Chieffo A, Montorfano M. Michev I et al. Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions. Eur Heart J 2005;26:1056-62.
80. Suttorp M. Primary Stenting of Occluded Native Coronary Arteries-the PRISON II study. Transcatheter Cardiovascular Therapeutics Conference; 2005, October 16-21, Washington, DC.
81. Kastrati A, Schömig A, Dirschinger J, Mehilli J, Dotzer F, von Welser N et al. A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries. Circulation 2000;102:2593-8.
82. Park SW, Lee CW, Hong MK, Kim JJ, Cho GY, Nah DY et al. Randomized comparison of coronary stenting with optimal balloon angioplasty for treatment of lesions in small coronary arteries. Eur Heart J 2000;21:1785-9.
83. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-5.
84. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
85. Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004;292:2727-34.
86. Popma JJ. Paclitaxel Eluting Coronary Stent Trials - Latest Data, Latest Caveats. La Jolla, CA: Scripps Clinic Coronary Interventions; 2005.
87. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
88. Pache J, Dibra A, Mehilli J, Dirschinger J, Schomig A, Kastrati A. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur Heart J 2005;26:1262-8.
89. Dawkins KD, Grube E, Guagliumi G, Banning AP. Zmudka K, Colombo A et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multi-center, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005;112:3306-13.
90. Aoki J, Ong AT, Rodriguez Granillo GA, McFadden EP, van Mieghem CA, Valgimigli M et al. "Full metal jacket" (stented length > or =64 mm) using drug-eluting stents for de novo coronary artery lesions. Am Heart J 2005;150:994-9.
91. Savage MP, Douglas JS Jr, Fischman DL, Pepine CJ, King SB 3rd, Werner JA et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997;337:740-7.
92. Costa M, Angiolillo DJ, Teirstein P, Gilmore P, Leon M, Moses J et al. Sirolimus-eluting stents for treatment of complex bypass graft disease: insights from the SECURE registry. J Invasive Cardiol 2005;17:396-8.
93. Ge L, Iakovou I, Sangiorgi GM, Chieffo A, Melzi G, Cosgrave J et al. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol 2005;45:989-94.
94. Lee MS, Shah AP, Aragon J, Jamali A, Dohad S, Kar S et al. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv 2005;66:507-11.
95. Tsuchida K, Ong AT, Aoki J, van Mieghem CA, Rodriguez-Granillo GA, Valgimigli M et al. Immediate and one-year outcome of percutaneous intervention of saphenous vein graft disease with paclitaxel-eluting stents. Am J Cardiol 2005;96:395-8.
96. Price MJ, Sawhney N, Kao JA, Madrid A, Schatz RA, Teirstein PS. Clinical outcomes after sirolimus-eluting stent implantation for de novo saphenous vein graft lesions. Catheter Cardiovasc Interv 2005;65:208-11.
97. Hoye A, Lemos PA, Arampatzis CA, Saia F, Tanabe K, Degertekin M et al. Effectiveness of the sirolimus-eluting stent in the treatment of saphenous vein graft disease. J Invasive Cardiol 2004;16:230-3.
98. Hoffman SN, TenBrook JA, Wolf MP, Pauker SG, Salem DN, Wong JB. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes. J Am Coll Cardiol 2003;41:1293-304.
99. Orlic D, Bonizzoni E, Stankovic G, Airoldi F, Chieffo A, Corvaja N et al. Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation: immediate and mid-term results. J Am Coll Cardiol 2004;43:1154-60.
100. Serruys PW. Arterial Revascularization Therapies trial (ARTS II). American College of Cardiology Annual Scientific Session; 2005, March 6-9, Orlando, FL.
101. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schonberger JP et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344:1117-24.
102. Ellis SG, Hill CM, Lytle BW. Spectrum of surgical risk for left main coronary stenoses: benchmark for potentially competing percutaneous therapies. Am Heart J 1998;135:335-8.
103. Agostoni P, Valgimigli M, Van Mieghem CA, Rodriguez-Granillo GA, Aoki J, Ong AT et al. Comparison of early outcome of percutaneous coronary intervention for unprotected left main coronary artery disease in the drug-eluting stent era with versus without intravascular ultrasonic guidance. Am J Cardiol 2005;95:644-7.
104. Arampatzis CA, Lemos PA, Hoye A, Saia F, Tanabe K, van der Giessen WJ et al. Elective sirolimus-eluting stent implantation for left main coronary artery disease: six-month angiographic follow-up and 1-year clinical outcome. Catheter Cardiovasc Interv 2004;62:292-6; discussion 297.
105. Park SJ, Kim YH, Lee BK, Lee SW, Lee CW, Hong MK et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. J Am Coll Cardiol 2005;45:351-6.
106. Chieffo A, Stankovic G, Bonizzoni E, Tsagalou E, Iakovou I, Montorfano M et al. Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation 2005;111:791-5.
107. Valgimigli M, van Mieghem CA, Ong AT, Aoki J, Granillo GA, McFadden EP et al. Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation 2005;111:1383-9.
108. Lemos PA, Saia F, Hofma SH, Daemen J, Ong AT, Arampatzis CA et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol 2004;43:704-8.
109. Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005;293:2109-17.
110. Hofma SH, Ong AT, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Valgimigli M et al. One year clinical follow up of paclitaxel eluting stents for acute myocardial infarction compared with sirolimus eluting stents. Heart 2005;91:1176-80.
111. Kernis SJ. PREMIER Study. Transcatheter Cardiovascular Therapeutics Conference; 2005, October 16-21, Washington, DC.
112. Grundy SM, D'Agostino Sr RB, Mosca L, Burke GL, Wilson PW, Rader DJ et al. Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood institute workshop. Circulation 2001;104:491-6.
113. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998;32:1866-73.
114. Mehilli J, Kastrati A, Schuhlen H, Dibra A, Dotzer F, von Beckerath N et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004;110:3627-35.
115. Abizaid A, Costa MA, Blanchard D, Albertal M, Eltchaninoff H, Guagliumi G et al. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial. Eur Heart J 2004;25:107-12.
116. Moussa I, Leon MB, Bairn DS, O'Neill WW, Popma JJ, Buchbinder M et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004;109:2273-8.
117. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, Gomez-Hospital JA, Alfonso F, Hernandez-Antolin R et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005;112:2175-83.
118. Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 2005;45:1172-9.
119. Aoki J, Ong A, Rodriguez-Granillo G, VanMieghem C, Daemen J, Sonnenschein K et al. The efficacy of sirolimus-eluting stents versus bare metal stents for diabetic patients undergoing elective percutaneous coronary intervention. J Invasive Cardiol 2005;17:344-8.
120. Ong AT, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Valgimigli M, Tsuchida K et al. Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). Am J Cardiol 2005;96:358-62.
121. Kuchulakanti PK, Torguson R, Canos D, Rha SW, Chu WW, Clavijo L et al. Impact of treatment of coronary artery disease with sirolimus-eluting stents on outcomes of diabetic and nondiabetic patients. Am J Cardiol 2005;96:1100-6.
122. Yang TH, Park SW, Hong MK, Park DW, Park KM, Kim YH et al. Impact of diabetes mellitus on angiographic and clinical outcomes in the drug-eluting stents era. Am J Cardiol 2005;96:1389-92.